Study on the adjuvant therapy of low birth weight infants with sepsis by IgM-rich immunoglobulin

Abstract

Abstract:

AIM: To evaluate the effect of IgM-enriched immunoglobulin treatment on clinical and laboratory parameters in very low birthweight neonates with nosocomial sepsis after pentaglobin treatment. METHODS: A total of 53 very low birth weight childern who were treated in the hospital from February 2015 to February 2016 were recruited as the study objects and divided into two groups; the control group was treated with conventional therapies, while the treatment group was given IgM-enriched immunoglobulin as a support therapy in addition to antibiotics; 5 mL/kg per day of pentaglobin was infused over a 4-hour period on 3 consecutive days. Clinical and laboratory parameters were recorded before and after treatment. RESULTS: The indicators of both groups were significantly improved after treatment, but they were improved more significantly in the treatment than in the control group, there was significant difference (P＜0.05). The total effective rate of treatment was 82.1% in the treatment group, higher than that in the control group (64.0%), there was significant difference (P＜0.05). The incidence of complication was 28.6% in the treatment group during therapy, while 44.0% in the control group, there was significant difference (P＜0.05). CONCLUSION: Pentaglobin treatment of nosocomial sepsis could be used as an adjunct therapy in very low birthweight neonates.

Key words: IgM-enriched immunoglobulins, sepsis, very low birthweight neonates, adjuvant therapy

CLC Number:

R722

YANG Zuqin, WANG Ying, CHEN Yingying. Study on the adjuvant therapy of low birth weight infants with sepsis by IgM-rich immunoglobulin[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(2): 174-178.

References

［1］Chirico G, Cortinovis S, Fonte C, et al. Bacterial sepsis［J］. Chemother, 2007, 19 Suppl 2(2): 28-30.
［2］Oba Y, Iwata K. Treatment of neonatal sepsis with immune globulin［J］. N Engl J Med, 2012, 366(1): 91.
［3］胡小华, 傅建平, 杨磊, 等. 低分子肝素治疗新生儿败血症的临床疗效评估［J］. 医学理论与实践, 2016, 29(11): 1489-1491.
［4］马友凤, 唐军, 李志博, 等. 免疫球蛋白对极低出生体重儿预防感染的临床研究［J］. 中华医院感染学杂志, 2015, 25(2): 455-457.
［5］马爱萍. 益气活血运脾方对反复呼吸道感染患儿免疫功能的影响［J］. 长春中医药大学学报, 2016, 32(3): 589-561.
［6］李素华, 陈益平, 王洪姣, 等. 免疫球蛋白治疗重症EV71感染疗效评估［J］. 中国基层医药, 2013, 20(17): 2569-2571.
［7］Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates［J］. Cochrane Database Syst Rev, 2015, 27(3): CD001239.
［8］Capasso L, Borrelli AC, Ferrara T, et al. Immunoglobulins in neonatal sepsis: has the final word been said［J］. Early Hum Dev, 2014, 90 Suppl 2: S47-S49.
［9］Di Rosa R, Pietrosanti M, Luzi G, et al. Polyclonal intravenous immunoglobulin: an important additional strategy in sepsis［J］. Eur J Intern Med, 2014, 25(6): 511-516.
［10］Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or proven infection in neonates［J］. Cochrane Database Syst Rev, 2013, 2(7): CD001239.
［11］Akdag A, Dilmen U, Haque K, et al. Role of pentoxifylline and/or IgM-enriched intravenous immunoglobulin in the management of neonatal sepsis［J］. Am J Perinatol, 2014, 31(10): 905-912.
［12］Shane AL, Stoll BJ. Recent developments and current issues in the epidemiology, diagnosis, and management of bacterial and fungal neonatal sepsis［J］. Am J Perinatol, 2013, 30(2): 131-141.
［13］Capasso L, Borrelli AC, Parrella C, et al. Are IgM-enriched immunoglobulins an effective adjuvant septic VLBW infants［J］. Ital J Pediatr, 2013, 39(1): 1-4.
［14］Shah BA, Padbury JF. Neonatal sepsis: an old problem with new insights［J］. Virulence, 2014, 5(1): 170-178.
［15］Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes［J］. J Infect, 2014, 68 Suppl 1: S24-S32.

[1]	XING Bomin, GUO Na, NING Haihui, DING Xinyun, MA Yuqing. Effects of Rho kinase inhibitors on septic liver injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 544-550.
[2]	HE Rui, TENG Wenbin, YAO Liuxu, SHAN Yue, ZHU Shengmei, LI Yuhong. Protective effect of hypoxia inducible factor-1α on intestinal mucosal barrier in sepsis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(3): 264-270.
[3]	LI Hui, LI Jun, HUAN Suqin, LI Yuhong, FAN Jun. Protection effect of dexmedetomidine against sepsis-induced intestinal mucosal barrier injury by up-regulating hypoxia inducible factor-1ɑ in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1386-1392.
[4]	YANG Huifang, LUO Ying, ZHAO Li. Effects of dexmedetomidine on renal function and serum inflammatory factors in sepsis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(8): 857-861.
[5]	RU Caiwang, YUAN Tianming, YANG Bingfen, WU Fugen, LIN Yingrong, MO Miaojun. Effects of imipenem-cilastatin sodium combined with immunoglobulin on serum PCT, hs-CRP and TNF-α in children with baby sepsis complicated with disseminated intravascular coagulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 559-565.
[6]	XUE Hua, LU Lili, XIANG Hui, QIAN Zhenhua. Curative efficacy of ulinastatin combined with hydrocortisone in treatment of severe sepsis secondary shock and effects on serum factor levels [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 313-317.
[7]	QIAO Yang, CHEN Qun, YANG Guang,CAO Yingya, LU Weihua. iTRAQ technology based differences of protein expression in sepsis-associated encephalopathy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(11): 1269-1274.
[8]	CAI Yun, XU Jinlong, ZHANG Mao. Pharmacokinetic of piperacillin/tazobactam in patients with sepsis during continuous venovenous hemodiafiltration [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(8): 905-911.
[9]	WEI Liuping, WU Qing, YIN Nange, YANG Bin, MAO Jinxiao. Effect and safety of lactoferrin for prevention of late-onset sepsis in premature neonates: a systematic review [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 653-660.
[10]	FANG Jingjing, TAO Jing, HUANG Qin, SHI Chaolu, YAN Biqing, GAI Lei, LI Xuguang. Effects of platelet activation on renal tubular epithelial cells in sepsis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 283-289.
[11]	YANG Yong, DENG Xianghui, HE Runzhi, HUANG Jia. Effects of hydrocortisone sodium succinate continuous intravenous infusion in the treatment of severe septic shock [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(11): 1297-1301.
[12]	WU Yonglei, WANG Dan, ZHANG Suiyang, WANG Ying, SUN Qin. Pharmacokinetics and pharmacodynamics of meropene administered by traditional prolonged infusion or optimized prolonged infusion in different tissues of septic rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 767-774.
[13]	JIANG Sanya, SHAN Yabing, CHEN Wenbin. Comparison study of modified FOLFOX6 combined with durative transfusion of endostatin as neoadjuvant treatment vs. treatment without endostatin for locally advanced rectal cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 674-679.
[14]	WANG Jian，ZHANG Wen. Correlation and clinical value of PCT, SVRI, SOFA in sepsis patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 443-447.
[15]	LI Pan, ZHAO Yi-bo, LI Xiao-li, LI Bin, ZHOU Hong. The sensitivity of LPS tolerance mice to Escherichia coli is mediated through modulation of pro-inflammatory cytokine release [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2015, 20(3): 261-265.